title: Impact of percutaneous coronary intervention on biomarker levels in patients in the subacute phase following myocardial infarction: the Occluded Artery Trial (OAT) biomarker ancillary study.
abstract: BACKGROUND
  The purpose of the Occluded Artery Trial (OAT) Biomarker substudy was to evaluate the impact of infarct related artery (IRA) revascularization on serial levels of N-terminal prohormone of brain natriuretic peptide (NT-proBNP) and dynamics of other biomarkers related to left ventricular remodeling, fibrosis and angiogenesis.
  
  
  METHODS
  Patients were eligible for OAT-Biomarker based on the main OAT criteria. Of 70 patients (age 60.8 ± 8.8, 25% women) enrolled in the substudy, 37 were randomized to percutaneous coronary intervention (PCI) and 33 to optimal medical therapy alone. Baseline serum samples were obtained prior to OAT randomization with follow up samples taken at one year. The primary outcome was percent change of NT-proBNP from baseline to 1 year. The secondary outcomes were respective changes of matrix metalloproteinases (MMP) 2 and 9, tissue inhibitor of matrix metalloproteinase 2 (TIMP-2), Vascular Endothelial Growth Factor (VEGF), and Galectin-3.
  
  
  RESULTS
  Paired (baseline and one-year) serum samples were obtained in 62 subjects. Baseline median NT-proBNP level was 944.8 (455.3, 1533) ng/L and decreased by 69% during follow-up (p < 0.0001). Baseline MMP-2 and TIMP-2 levels increased significantly from baseline to follow-up (p = 0.034, and p = 0.027 respectively), while MMP-9 level decreased from baseline (p = 0.038). Levels of VEGF and Galectin-3 remained stable at one year (p = NS for both). No impact of IRA revascularization on any biomarker dynamics were noted.
  
  
  CONCLUSIONS
  There were significant changes in measured biomarkers related to LV remodeling, stress, and fibrosis following MI between 0 and 12 month. Establishing infarct vessel patency utilizing stenting 24 hours-28 days post MI did not however influence the biomarkers' release.
authors.forename: Mariusz
authors.initials: M
authors.lastname: Kruk
authors.forename: Venu
authors.initials: V
authors.lastname: Menon
authors.forename: Jacek
authors.initials: J
authors.lastname: Kądziela
authors.forename: Zygmunt
authors.initials: Z
authors.lastname: Sadowski
authors.forename: Witold
authors.initials: W
authors.lastname: Rużyłło
authors.forename: Jadwiga
authors.initials: J
authors.lastname: Janas
authors.forename: Marek
authors.initials: M
authors.lastname: Roik
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Opolski
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Zmudka
authors.forename: Piotr
authors.initials: P
authors.lastname: Czunko
authors.forename: Michal
authors.initials: M
authors.lastname: Kurowski
authors.forename: Benita
authors.initials: B
authors.lastname: Busz-Papież
authors.forename: Elzbieta
authors.initials: E
authors.lastname: Zinka
authors.forename: Wojciech
authors.initials: W
authors.lastname: Jablonski
authors.forename: Krystyna
authors.initials: K
authors.lastname: Jaworska
authors.forename: Anna
authors.initials: A
authors.lastname: Raczynska
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Skonieczny
authors.forename: Sandra
authors.initials: S
authors.lastname: Forman
authors.forename: Daner
authors.initials: D
authors.lastname: Li
authors.affiliation: New York University School of Medicine, New York, New York, USA. Judith.Hochman@nyumc.org.
authors.forename: Judith
authors.initials: J
authors.lastname: Hochman
mesh_terms: D000368:Aged; D015415:Biomarkers; D015331:Cohort Studies; D054059:Coronary Occlusion / Q000097:blood* / Q000175:diagnosis* / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000097:blood; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000175:diagnosis* / Q000601:surgery; D020097:Natriuretic Peptide, Brain / Q000097:blood; D010446:Peptide Fragments / Q000097:blood; D062645:Percutaneous Coronary Intervention / Q000639:trends; D019716:Tissue Inhibitor of Metalloproteinase-2 / Q000097:blood; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000097:blood
chemical_list: D015415:Biomarkers; D010446:Peptide Fragments; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C109794:pro-brain natriuretic peptide (1-76); D020097:Natriuretic Peptide, Brain; D019716:Tissue Inhibitor of Metalloproteinase-2; D020778:Matrix Metalloproteinase 2